Recursion Pharmaceuticals (NASDAQ: RXRX) has been a pioneer in using artificial intelligence (AI) to improve the drug ...

AI-based drug developer Recursion’s stock barely moved Wednesday, then dropped Thursday and Friday, after reporting mixed third quarter results, setting the stage for future pipeline announcements—and ...

Recursion Pharmaceuticals (RXRX) posted another year of accelerating losses, with net losses growing at 35.2% per year over the last five years. Despite ongoing red ink, revenue is forecast to climb ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and ...

Recursion Pharmaceuticals, Inc (($RXRX)) has held its Q3 earnings call. Read on for the main highlights of the call. Recursion Pharmaceuticals, ...

Salt Lake City, Utah, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that its Board ...

The ability to respond to changing surroundings was once considered exclusive to complex living organisms. Then came ...

And while these personas can be generated through most any chatbot, it seems that OpenAI’s 4o model is the origin point and, ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

It is certainly possible that today’s bottlenecks will prove to be rather short-lived as companies increasingly learn to ...

Recursion announced Najat Khan, PhD, currently chief R&D and commercial officer and a board member, will succeed co-founder and CEO Chris Gibson, PhD as CEO and president. Khan will also continue in ...